Stage III NSCLC
Conditions
Interventions
Bronchoalveolar lavage
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: • Age > 18-85 years; • Clinical suspicion of lung tumor with mediastinal lymph node involvement based on enlarged lymph nodes on CT thorax or FDG uptake on PET-CT conform ESMO guidelines; • Planned bronchoscopy with endobronchial ultrasound (EBUS) with sedation (Propofol or benzodiazepine) for standard diagnostic work -up; • Clinical performance adequate for undergoing EBUS (according to pulmonary physician ordering the diagnostic procedure).
Exclusion criteria
Exclusion criteria: • Clinical performance too low to undergo EBUS according to pulmonary physician ordering the diagnostic procedure; • Suspicion of metastasis or stage IV disease on PET-CT or CT-thorax; • Inadequate understanding of the Dutch language in speech and writing. • Clinical performance too low to receive chemoradiotherapy or proton therapy; • Significant co-morbidities such as end stage renal disease, severe cardiovascular disease, severe psychiatric disease, end stage COPD, or other comorbidity with limited expected survival (3; • Known pre-existent diagnosis of lung fibrosis or newly diagnosed lung fibrosis before start of the study; • Previous thoracic radiation-treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A significant difference in the number of yH2AX foci (double strand DNA damage) per cell induced by in vitro radiation between patient-specific normal epithelial cells from patients with grade 2 or higher pneumonitis or fibrosis following chemoradiation or proton therapy based on CTCAE scoring system and patients with grade 1 or lower pneumonitis or fibrosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Other in vitro measurements of e.g. EMT, changes in lung function, CT-densitometry, lung function and diffusion capacity | — |
Contacts
Public ContactMerian Kuipers
Leiden University Medical Centre
Outcome results
None listed